# Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

> **NCT05266937** · PHASE2 · UNKNOWN · sponsor: **Consorzio Oncotech** · enrollment: 49 (actual)

## Conditions studied

- Metastatic Breast Cancer
- Triple Negative Breast Cancer
- PD-L1 Gene Mutation

## Interventions

- **COMBINATION_PRODUCT:** Atezolizumab,Paclitaxel, Carboplatin

## Key facts

- **NCT ID:** NCT05266937
- **Lead sponsor:** Consorzio Oncotech
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-07-03
- **Primary completion:** 2024-07-03
- **Final completion:** 2024-07-03
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2024-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05266937

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05266937, "Atezolizumab Plus CArboplatin Plus Nab-paclitaxel". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05266937. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*